Skip to main content
LNTH
NASDAQ Life Sciences

Lantheus Shareholders Approve Significant Equity Plan Expansion and Board Declassification

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$86
Mkt Cap
$5.566B
52W Low
$47.25
52W High
$108.91
52W Position info
82% above low
Off High info
21% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

LNTH sits 82% above its 52-week low of $47.25.

Summary

Lantheus Holdings, Inc. shareholders approved an amendment to its equity incentive plan, increasing shares reserved for issuance by 2 million, and also voted to declassify the Board of Directors.


Key Events · Financing and Capital Events · LNTH

  • Equity Incentive Plan Expanded

    Shareholders approved an increase of 2,000,000 shares reserved for issuance under the Amended and Restated 2026 Equity Incentive Plan. This represents a substantial potential future dilution for existing shareholders.

  • Board Declassification Approved

    The company's shareholders approved an amendment to declassify the Board of Directors over a three-year period, transitioning to annual elections for all directors.

  • Director Compensation Limits Revised

    Non-employee director compensation limits were changed from a share-based cap to a dollar-based cap of $1.25 million for the first year of appointment and $750,000 annually thereafter.

  • Routine Annual Meeting Approvals

    Shareholders also elected four Class II directors, provided advisory approval for executive compensation, and ratified the appointment of Deloitte & Touche LLP as independent auditors.


Analysis · LNTH · Life Sciences

The approval of the Amended and Restated 2026 Equity Incentive Plan, which adds 2 million shares for future awards, represents a substantial potential dilution for existing shareholders. This capital is intended for employee retention and motivation, crucial for executing the company's strategic initiatives. Concurrently, the company's move to declassify its Board of Directors over a three-year period is a positive corporate governance development, enhancing accountability to shareholders. Investors should weigh the long-term benefits of talent incentives and improved governance against the immediate dilutive impact.

At the time of this filing, LNTH was trading at $86.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $47.25 to $108.91. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LNTH - Latest Insights

LNTH
Jul 27, 2026, 5:30 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $106.70
Real-time Price: $98.00 info
Change: -$8.70 (-8%) info
Market Cap: $6.487B info
LNTH
Jun 26, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $109.80
Real-time Price: $98.00 info
Change: -$11.80 (-11%) info
Market Cap: $6.487B info
LNTH
Jun 02, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $97.28
Real-time Price: $98.00 info
Change: +$0.7201 (+0.74%) info
Market Cap: $6.487B info
LNTH
May 07, 2026, 7:44 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $89.90
Real-time Price: $98.00 info
Change: +$8.10 (+9%) info
Market Cap: $6.487B info
LNTH
May 07, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $89.90
Real-time Price: $98.00 info
Change: +$8.10 (+9%) info
Market Cap: $6.487B info